Parkinson's Disease Research

Parkinson's disease (PD) is a degenerative disease of the central nervous system that often impairs motor skills, speech, and other functions. Symptoms of the disease include resting tremor, bradykinesia and rigidity. The primary symptoms are the result of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. Symptoms of the disease appear once 50-80% of dopamine neurons have died. Parkinson's disease is both chronic and progressive.

Parkinson's Disease Research Products Targets

Products for Parkinson's Disease Research - Page 8

  1. Cat.No. Product Name Information/Activity
  2. BCC6794 NCS-382 520505-01-5 NCS-382 chemical structure
  3. BCC6231 Pentobarbital sodium salt 57-33-0 Pentobarbital sodium salt chemical structure
  4. BCC7453 Pentylenetetrazole 54-95-5 Pentylenetetrazole chemical structure
  5. BCC6230 Phenobarbital sodium salt 57-30-7 Phenobarbital sodium salt chemical structure
  6. BCC2156 Valproic acid sodium salt (Sodium valproate) Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches. Valproic acid sodium salt (Sodium valproate) chemical structure
  7. BCC2512 Zonisamide Zonisamide is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug. Zonisamide chemical structure
  8. BCC6218 CZC 54252 hydrochloride CZC-54252 is a potent inhibitor of LRRK2 with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2 respectively. CZC 54252 hydrochloride chemical structure
  9. BCC6243 GSK2578215A GSK2578215A is a potent and highly selective LRRK2 inhibitor, which exhibits IC50s of around 10 nM against both wild-type LRRK2 and the G2019S mutant. GSK2578215A chemical structure
  10. BCC1706 LRRK2-IN-1 LRRK2-IN-1 is a potent and selective LRRK2 inhibitor with IC50 of 6 nM and 13 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively. LRRK2-IN-1 chemical structure
  11. BCC5589 PF-06447475 PF-06447475 is a highly potent, selective and brain penetrant LRRK2 inhibitor with an IC50 of 3 nM. PF-06447475 chemical structure

Items 71 to 80 of 752 total